Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice

Rafael Campos Polo
Consuelo Rubio Sánchez
Diego Manuel García Guisado
María José Díaz Luque

Unit of Retina, Department of Ophthalmology, Hospital Virgen del Puerto, Plasencia, Cáceres, Spain

Purpose: To assess the effectiveness and safety of intravitreal aflibercept in clinically significant diabetic macular edema (DME) in daily clinical practice.

Methods: Prospective, open-label, single-center study. Anti-vascular endothelial growth factor naïve patients with clinically significant DME received intravitreal injections of aflibercept 2 mg, five monthly doses followed by a fixed schedule every 2 months for 12 months. The mean change in best-corrected visual acuity (BCVA) (Early Treatment Diabetic Retinopathy Study [ETDRS] letters) was the primary outcome.

Results: The mean BCVA improved significantly as compared with baseline at 12 months of treatment (47.3 [14.2] vs 62.2 [13.9] ETDRS letters, \( P<0.001 \)). Significant improvement in BCVA was already observed at visit 2 after the loading doses of aflibercept. At 12 months, gains in ETDRS letters were documented in all eyes (100%), with gains \( \geq 10 \) letters in 89.6%, \( \geq 15 \) letters in 65.5%, and \( \geq 20 \) letters in 6.9% (n=2). A significant reduction in central macular thickness from a mean of 460.5 (11.8) \( \mu \)m at baseline to 229.0 (43.8) \( \mu \)m at 12 months (\( P<0.001 \)) was observed. Significant reductions of central macular thickness were already observed after the loading doses and continued lowering throughout the study period. No adverse events occurred.

Conclusion: Aflibercept as a first-line therapy was effective and well tolerated for treating clinically significant DME in naïve patients in daily practice. Successful results in terms of improvement of visual and reduction in central macular thickness contribute to provide evidence for the positioning of aflibercept as a first-line indication of newly diagnosed clinically significant DME.

Keywords: aflibercept, central macular thickness, diabetic macular edema, routine clinical practice, visual acuity

Introduction

Diabetic macular edema (DME) is a major cause of vision loss associated with diabetic retinopathy and is characterized by exudation and accumulation of extracellular fluid in the macula secondary to an increase in vascular permeability.\(^1,2\) A review conducted in 2012 suggested that up to 7% of people with diabetes may have DME.\(^3\) Among population-based studies, the prevalence of DME in patients with type 1 diabetes was between 4.2% and 7.9%. In patients with type 2 diabetes, it was between 1.4% and 12.8%.\(^4\) However, the global prevalence of DME is likely to increase along with the increasing prevalence of diabetes mellitus, particularly in view of the current epidemics of type 2 diabetes.\(^5\)

Although the pathogenesis of DME is multifactorial, including capillary endothelial vascular dysfunction, local inflammatory activity, cellular hypoxia, oxidative stress,
breakdown of the blood–retinal barrier, and retinal neurodegeneration, the overexpression of vascular endothelial growth factor (VEGF) has been identified as a key contributor to the development of DME. The proteins VEGF-A, VEGF-B, and the placental growth factor (PIGF) are members of the VEGF family and are the most relevant for ocular disease. These proteins after binding to specific receptors (VEGFR-1 and VEGFR-2) initiate a cascade of events leading to vasculogenesis and angiogenesis. Awareness of the role of VEGF and inflammatory mediators in the pathogenesis of DME has prompted the development and widespread use of anti-VEGF inhibitors that can target these pathways. Anti-VEGF treatment has superseded macular laser treatment and is now the first-line therapy for DME involving the central macula.

The monoclonal antibodies bevacizumab and ranibizumab target VEGF-A isoforms, whereas aflibercept, unlike the monoclonal antibodies, is a soluble decoy receptor fusion protein that inhibits PIGF in addition to all isoforms of VEGF-A and VEGF-B. Also, aflibercept has a longer duration of action than other anti-VEGF agents and has a 100-fold greater binding affinity for VEGF-A than intravitreal ranibizumab, which confers the advantage of the potential for less frequent dosing of aflibercept, with substantial saving in cost and treatment burden to patients. The efficacy and safety of aflibercept in diabetic patients with DME were demonstrated in the landmark Phase III VISTA-DME and VIVID-DME studies. The administration of 2 mg of aflibercept every 4 weeks (2q4) or every 8 weeks (2q8) after five initial monthly doses was associated with significantly better functional and anatomical outcomes as compared with laser photocoagulation. These favorable outcomes were sustained through weeks 100 and 148. In the Protocol T study, aflibercept was significantly superior to ranibizumab and bevacizumab in the subset of patients with worse vision (Early Treatment Diabetic Retinopathy Study [ETDRS] letter score <69, equivalent to 20/50 or worse) at baseline. However, outside the framework of clinical trials, there is little evidence of real-life outcomes in patients with DME. Different studies have shown that converting unresponsive patients or those with persistent DME from bevacizumab or ranibizumab to aflibercept results in anatomical and vision improvements, but data in patients with treatment-naïve DME are lacking.

The purpose of the present study was to evaluate the effectiveness and safety profile of intravitreal aflibercept in the treatment-naïve patients with DME in daily clinical practice.

Methods

Study design and patients

This was a prospective, single-center, 12-month observational study carried out in a 240-bed district general hospital in Plasencia, Spain. The study protocol was approved by the Ethics Committee of Hospital Virgen del Puertó de Plasencia, Cáceres (Spain), and the study was conducted in accordance with the principles of the Declaration of Helsinki for the protection of human subjects. Written informed consent was obtained from all individual participants included in the study.

Patients of both sexes, aged >18 years, were enrolled during routine ophthalmologic appointments between March 2015 and March 2016. All patients who were treatment-naïve of anti-VEGF agents with clinically significant DME were eligible for enrollment. Clinically significant DME was diagnosed on clinical examination and confirmed by spectral-domain optical coherence tomography (SD-OCT) (Cirrus HD-OCT; Carl Zeiss Meditec, Dublin, CA, USA). Clinically significant DME was measured within 500 µm of the center of the macula and according to the ETDRS was defined upon slit lamp biomicroscopy as 1) thickening of the retina at or within 500 µm of the center of the macula; or 2) hard exudate at or within 500 µm of the center of the macula associated with thickening of adjacent retina; or 3) a zone of retinal thickening 1 disc area or larger, any part of which is within 1 disc diameter of the center of the macula.

To be included in the study, patients should be able to receive intravitreal treatment with aflibercept and not have undergone major ocular surgical procedures in the 4 months prior to the study or anticipated to undergo within the next 6 months after enrollment. Patients unable to participate in the study according to criteria of the ophthalmologist in charge and those who refused to sign the written informed consent were excluded. The study was carried out under conditions of daily practice. The duration of the study was 12 months.

Study procedures

All patients were treated with intravitreal aflibercept according to the Summary of Product Characteristics (SPC) and the treating physician’s normal clinical practice. Patients received five loading doses of aflibercept injections (2 mg/0.05 mL, Eylea®; Bayer Hispania, S.L., Barcelona, Spain) every 4 weeks and then a fixed dose every 8 weeks. Injection of intravitreal aflibercept was performed as an outpatient procedure using topical anesthesia with lidocaine eye drops and strict sterile conditions. After topical anesthesia, the ocular surface and the lid were disinfected with povidone-iodine.
Intravitreal injection of aflibercept was carried out using a 30-gauge needle at 3.5 mm posterior to the limbus. The injection site was compressed by cotton swab to avoid reflux, and the fundus was examined to rule out any complication and to check perfusion of the retinal artery.

Patients were visited at the outpatient clinics of the Service of Ophthalmology at baseline, after the five loading doses, and at 2-month intervals thereafter, with a total of five visits (visit 1 baseline, visit 2 at 5 months, visit 3 at 7 months, visit 4 at 9 months, and visit 5 at 12 months). At each visit, a complete ophthalmologic examination was performed, which included slit lamp examination, best corrected visual acuity (BCVA) using an ETDRS optotype at 2 m distance from the observer, funduscopy, central subfield macular thickness, and vitreomacular adhesion (VMA) and/or vitreomacular traction (VMT) by SD-OCT. The presence of subretinal fluid and/or subfoveal or extrafoveal retinal cysts was assessed at the final visit. Also, serum glycosylated hemoglobin (HbA1c) levels were measured at baseline and at 6 and 12 months. Laser photocoagulation was included in the protocol in case of decrease in BCVA during the study period.

**Study outcomes**

The mean changes in BCVA (ETDRS letters) from baseline to the final study visit at 12 months were the primary outcomes of the study. Secondary outcomes were changes in central macular thickness from baseline to the final study visit at 12 months, changes in BCVA and central macular thickness after the five loading doses at each study visit, presence of VMA/VMT, changes in serum HbA1c levels at 6 and 12 months as compared with baseline, and the proportion of patients with subretinal fluid and/or retinal cysts at 12 months.

**Statistical analysis**

Categorical data are expressed as frequencies and percentages, and continuous data as mean and SD. Continuous variables during the different time points throughout the study period were analyzed with the Student’s t-test for paired samples. Statistical significance was set at \( P < 0.05 \). The Statistical Analysis Systems (SAS Institute, Cary, NC, USA) version 9.4 was used for analysis.

**Results**

A total of 29 eyes from 15 patients were included in the study and were followed for 12 months. There were 11 men and 4 women, with a mean age of 55.6 years (range 36–76 years). Baseline BCVA ranged between 20 and 72 ETDRS letters.

At baseline, VMA/VMT was documented in nine eyes (31.9%) associated with epiretinal membrane (ERM) in five. In these five patients, the diagnosis of incipient ERM was established by OCT. At the end of the follow-up period, VMA/VMT was still present in three eyes (10.3%), with ERM in one. Also, subretinal fluid and/or extrafoveal retinal cysts were present in all eyes at baseline. At the final visit at month 12, subretinal fluid was detected in 18 eyes (62.1%) and extrafoveal retinal cysts in 5 (17.2%).

In relation to the primary outcome of the study (Figure 1), the mean BCVA improved significantly as compared with baseline at 12 months of treatment (47.3 [14.2] vs 62.2 [13.9] ETDRS letters, \( P < 0.001 \)). The mean difference was 14.9 (6.5) (95% CI 12.5 to 17.4). Significant improvement in BCVA was already observed at visit 2 after the loading doses of aflibercept (47.3 [14.2] vs 60.3 [14.0] ETDRS letters, \( P < 0.001 \)), with a mean difference of 13.0 (5.9) (95% CI 10.7 to 15.2). Comparisons of BCVA between baseline and results at visits 3, 4, and 5 were also statistically significant (\( P < 0.001 \)). However, changes in BCVA between follow-up visits were not significant (Table 1). At 12 months, gains in ETDRS letters were documented in all eyes (100%), with gains \( \geq 10 \) letters in 89.6% (n=26), \( \geq 15 \) letters in 65.5% (n=19), and \( \geq 20 \) letters in 6.9% (n=2). There were no cases of vision loss.

Treatment with intravitreal aflibercept was associated with a significant reduction in central macular thickness from a mean of 460.5 (11.8) µm at baseline to 229.0 (43.8) µm at 12 months (\( P < 0.001 \)). The mean difference was –231.5 (126.6) µm (95% CI –279.7 to –183.3). Significant reductions in central macular thickness were already observed at visit 2 after the loading doses of aflibercept (Figure 2). Comparisons of central macular thickness between baseline and
and results at visits 3, 4, and 5 were also statistically significant ($P<0.001$). Moreover, changes in central macular thickness between visits 3 to 4 and 4 to 5 were also statistically significant (Table 2).

In relation to serum levels of HbA1c, mean (SD) baseline levels were 8.0% (0.5) as compared to 7.9% (0.3) at 6 months ($P=0.247$) and 7.9% (0.5) at 12 months ($P=0.280$).

Ocular or systemic adverse events related to intravitreal treatment with aflibercept were not recorded. None of the patients received other treatment (e.g., cataract surgery and refractive surgery) during the 12-month study period.

**Discussion**

The present prospective study carried out in daily clinical practice confirms the effectiveness of intravitreal aflibercept for the treatment of patients with clinically significant DME and naïve to anti-VEGF treatment. Adverse events related to intravitreal aflibercept were not recorded. Our data are consistent with optimal vision gains and anatomic improvement previously reported in the large double-masked, randomized Phase III clinical trials VISTA-DME and VIVID-DME.\[^{24,25}\]

In these trials, patients were randomized to intravitreal aflibercept injection 2 mg every 4 weeks (2q4; n=290), 2 mg every 8 weeks (2q8; n=286) after five initial monthly doses, or macular laser photocoagulation (n=286). The primary efficacy end point was the change from baseline in BCVA in ETDRS letters at week 52. Treatment with aflibercept was associated with gains in ETDRS letters of 12.5, 10.7, and 0.2 in the 2q4, 2q8, and laser groups, respectively. Results obtained in our study with a mean difference of 13.0 ETDRS letters are even more favorable than mean BCVA gains reported in these trials. Also, in relation to anatomic improvement, reductions in central macular thickness with a mean difference of 231.5 μm found in the present clinical series are greater than 185.9 and 195.0 μm, and 183.1 and 192.4 μm reported for the 2q4 and 2q8 regimens of aflibercept, respectively, in the two randomized trials.

There are limited data on the effect of aflibercept for the management of DME in the real-world setting, and the majority of previously published studies have evaluated the efficacy of aflibercept in patients with DME unresponsive to previous anti-VEGF therapy.\[^{28–33}\] Recently, a randomized prospective study conducted in daily practice in 70 eyes with DME divided into two groups of 35 eyes each, compared intravitreal aflibercept and ranibizumab after a follow-up of 12 months.\[^{35}\] At 12 months, similar efficacy for both drugs in the treatment of DME in eyes with moderate visual loss was demonstrated, but with less number of drug rejections and treatment burden for aflibercept. In this study, it is not explicitly mentioned if patients were naïve to anti-VEGF treatment nor if they had clinically significant DME; only three loading doses of aflibercept were administered unlike five loading doses recommended in the SPC; and anti-VEGF was re-injected if the macular edema was persistent or if the visual acuity or central macular thickness worsened, which is different from the regimen of fixed

### Table 1 Changes in BCVA in 29 study eyes from 15 patients with DME

<table>
<thead>
<tr>
<th>Time points</th>
<th>BCVA ETDRS letters</th>
<th>Crude difference</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (SD)</td>
<td>95% CI</td>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Baseline</td>
<td>47.3 (14.2)</td>
<td>41.9 to 52.7</td>
<td>13.0 (5.9)</td>
</tr>
<tr>
<td>Intravitreal aflibercept</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visit 2 (5 months)</td>
<td>60.3 (14.0)</td>
<td>55.9 to 65.7</td>
<td>13.4 (6.8)</td>
</tr>
<tr>
<td>Visit 3 (7 months)</td>
<td>60.8 (13.8)</td>
<td>55.5 to 66.0</td>
<td>13.4 (7.0)</td>
</tr>
<tr>
<td>Visit 4 (9 months)</td>
<td>60.7 (14.0)</td>
<td>55.4 to 66.0</td>
<td>14.9 (6.5)</td>
</tr>
<tr>
<td>Visit 5 (12 months)</td>
<td>62.2 (13.8)</td>
<td>57.0 to 67.5</td>
<td>0.48 (4.9)</td>
</tr>
<tr>
<td>Visit 3 vs visit 2</td>
<td>−0.03 (6.1)</td>
<td>−2.4 to 2.3</td>
<td>1.5 (4.2)</td>
</tr>
<tr>
<td>Visit 4 vs visit 3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visit 5 vs visit 4</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** BCVA, best-corrected visual acuity; DME, diabetic macular edema; ETDRS, Early Treatment Diabetic Retinopathy Study.

![Figure 2](https://www.dovepress.com/forpersonaluseonly.png) Changes in central macular thickness from baseline to 12 months after treatment with intravitreal aflibercept.
doses at 2-month intervals used in our study. However, this randomized study also provides evidence of the effectiveness of aflibercept in patients with DME who attended the routine clinical setting.

In this study, we report the prospective data collected in the real-world setting from 15 patients (29 eyes) with clinically significant DME who were naïve for anti-VEGF therapy, followed for 12 months, in whom aflibercept was indicated as a first-line therapy and administered according to technical specifications of the drug. Aflibercept as the first choice of treatment in these patients resulted in a prompt and substantial functional and anatomic improvement, with statistically significant differences as compared with pretreatment values at 5 months of treatment (after the loading dose of the drug). All patients maintained improved vision at 12 months. In addition, further significant reductions in central foveal thickness along the study period were observed. Also, resolution of VMA/VMT was found in 66.7% of patients.

Limitations of the study include the small sample size and the open-label design where selection bias cannot be excluded, although recommended criteria for the definition of clinically significant DME were used. However, under routine daily practice circumstances, the present findings show that intravitreal treatment with aflibercept was useful as a first-line therapy in patients with treatment-naïve DME, with sustained BCVA improvement and reduction in central macular thickness.

**Acknowledgment**

The authors thank Marta Pulido, MD, for editing the manuscript and editorial assistance.

**Disclosure**

The authors report no conflicts of interest in this work.

References


**Table 2** Changes in central macular thickness in 29 study eyes from 15 patients with DME

<table>
<thead>
<tr>
<th>Time points</th>
<th>Central macular thickness (μm)</th>
<th>Crude difference</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (SD)</td>
<td>95% CI</td>
<td>Mean (SD)</td>
</tr>
<tr>
<td>Baseline</td>
<td>460.5 (111.8)</td>
<td>417.9 to 503.0</td>
<td></td>
</tr>
<tr>
<td>Intravitreal aflibercept</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visit 2 (5 months)</td>
<td>278.7 (47.7)</td>
<td>260.6 to 296.9</td>
<td>−181.8 (120.5)</td>
</tr>
<tr>
<td>Visit 3 (7 months)</td>
<td>273.9 (48.5)</td>
<td>255.4 to 292.4</td>
<td>−186.6 (108.6)</td>
</tr>
<tr>
<td>Visit 4 (9 months)</td>
<td>256.3 (50.3)</td>
<td>237.2 to 275.5</td>
<td>−204.1 (124.8)</td>
</tr>
<tr>
<td>Visit 5 (12 months)</td>
<td>229.0 (43.8)</td>
<td>212.3 to 245.6</td>
<td>−231.5 (126.6)</td>
</tr>
<tr>
<td>Visit 3 vs visit 2</td>
<td>−4.8 (45.1)</td>
<td>−22.0 to 12.3</td>
<td>0.569</td>
</tr>
<tr>
<td>Visit 4 vs visit 3</td>
<td>−17.5 (34.4)</td>
<td>−30.6 to −4.5</td>
<td>0.010</td>
</tr>
<tr>
<td>Visit 5 vs visit 4</td>
<td>−27.4 (35.0)</td>
<td>−40.7 to −14.1</td>
<td>0.001</td>
</tr>
</tbody>
</table>

**Abbreviation:** DME, diabetic macular edema.